TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Results of Operations and Financial Condition
On August 8, 2017, TRACON Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2017. A copy of this press release is furnished as Exhibit 99.1 hereto.
|
Item 2.02 |
Financial Statements and Exhibits. |
|
99.1 |
Press release issued by TRACON Pharmaceuticals, Inc. on August 8, 2017 announcing its financial results for the quarter ended June 30, 2017. |
Tracon Pharmaceuticals, Inc. ExhibitEX-99.1 2 tcon-ex991_6.htm EX-99.1 tcon-ex991_6.htm Exhibit 99.1 TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update San Diego,…To view the full exhibit click here
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
